Robert W. Huigens, III, [a] Hyang Yeon Lee, [a] Rahul Palchaudhuri, [a] Marco Macchia, [c] Adriano Martinelli, [c] Filippo Minutolo,* [c] and Paul J. Hergenrother* [a, b] Nearly a century ago, German scientist Otto Warburg observed that solid tumors deviate from most normal tissues in their ravenous consumption of glucose and high rates of aerobic glycolysis. [1] This dysfunctional metabolism has been proposed to convey a survival advantage to tumor cells, thus allowing them to proliferate in normoxic or hypoxic environments and to evade killing by the immune system.
[2] The molecular mechanisms underlying the Warburg effect have been elucidated, most notably that tumor cells overexpress the glucose transporter GLUT-1 [3] and enzymes of glycolysis, including lactate dehydrogenase isoform A (LDH-A). [4] Targeting dysregulated tumor-cell metabolism is emerging as a promising anticancer strategy. [2a] Herein we report the first demonstration of "dual targeting" of the Warburg effect by a glucose-conjugated LDH-A inhibitor, by exploiting both preferential glucose uptake and increased glycolysis in cancer cells (Figure 1 A) .
A common clinical application that utilizes the selective uptake of glucose into cancerous over normal tissues is the use of the radiolabeled glucose analogue 2-deoxy-2-( 18 F)fluorod-glucose ( 18 F-FDG). 18 F-FDG is a ubiquitous imaging tool for diagnosing and staging many types of cancers, including lung, breast, endometrial and colorectal carcinomas, several types of sarcomas, and both Hodgkin's and non-Hodgkin's lymphomas. [5] In addition, the conjugation to anticancer agents of glucose [6] or similar sugars potentially recognized by GLUT-1 receptors [7] offers potential selective targeting of cytotoxic drugs. [8] The most clinically advanced glycoconjugate, glufosfamide, has reached phase II and phase III clinical trials in Europe and the United States.
[9]
LDH-A, a key enzyme in glycolysis, catalyzes the reduction of pyruvate to lactate (Figure 1 A) , thereby generating NAD + and thus enabling continued glycolysis and ATP production in the absence of aerobic oxidation of NADH. [10] Much of the lactate produced in this reaction is excreted into the tumor microenvironment, thus acidifying it and limiting immune system access to tumor tissue. [11] Overexpression of LDH-A has been noted in numerous solid tumors and has been found to correlate with poor clinical outcome in patients; [12] these data have been corroborated by a number of studies demonstrating that cancer cells in which LDH-A expression was attenuated (by RNA interference) are less viable and less tumorigenic.
[13] Importantly, LDH-A inhibition is unlikely to harm normal tissues. LDH-A deficiency is present in the human population at a frequency of 0.0012: [14] individuals heterozygous for LDH-A deficiency have no clinical presentation; homozygous patients present with myoglobinuria only upon extreme exertion. [15] We recently reported the discovery of N-hydroxyindole (NHI)-based LDH-A inhibitors (e.g., NHI-1, Figure 1 B) as anticancer agents.
[16] Other classes of in vitro LDH-A inhibitor exist, [17] including the natural product gossypol, [18] its derivative FX-11, [19] the pyruvate mimetic oxamate, [20] the gallic acid derivative galloflavin, [21] compounds developed in a fragmentbased approach by AstraZeneca [22] and by ARIAD Pharmaceuticals, [23] and in screening by Genentech and GSK.
[24] However, NHI inhibitors are attractive candidates because of their facile synthesis, selective toxicity toward cancerous cells, and in vitro and cellculture efficacy.
[16] Thus NHIs constitute an outstanding compound class to demonstrate the concept of dually targeting the Warburg effect by linking glucose to a glycolytic enzyme inhibitor.
We previously reported compound NHI-1 (Figure 1 B) as a competitive inhibitor of LDH-A in vitro: it inhibited conversion of [
13 C]glucose to [ 13 C]lactate in HeLa cells when used at a high concentration (500 mm).
[16a] Later, methyl ester NHI-2 was found to inhibit LDH-A in vitro and to kill cancer cells in culture.
[16b]
Furthermore, NHI-2 proved to be stable after uptake by cancer cells, thus suggesting that its improved anti-proliferative activity is attributable to improved cell uptake compared to NHI-1.
[16b] In efforts to enhance tumor cell selectivity and efficacy of NHI-1 and NHI-2, glucose conjugates NHI-Glc-1 and NHI-Glc-2 (Figure 1 B) were synthesized and evaluated (synthetic routes are given in the Supporting Information).
In vitro evaluation with LDH-A revealed that non-conjugated NHI-1 and NHI-2
[16b] and glucose-conjugated derivatives (NHIGlc-1 and NHI-Glc-2) are competitive inhibitors of LDH-A by binding to the NADH binding pocket; conjugation with the sugar moiety lowered the inhibitory potency twofold (NHI-Glc-1) and sevenfold (NHI-Glc-2). To rule out inhibition by aggregation, additional assays were conducted in the presence of Triton X detergent and bovine serum albumin (BSA) under conditions described previously. [25] The NHI series (e.g., NHI-1, NHI-2, and NHI-Glc-2) retained its inhibitory potency against LDH-A in the presence of both Triton X and BSA ( Figure S1 ). Docking studies followed by molecular dynamic (MD) simulations were carried out to examine the interaction of the glucose conjugates with LDH-A. Starting from the average structure of the minimized LDH-A/NHI-1 complex that we recently reported, [16a] NHI-Glc-2 was docked to the protein by using GOLD 5.1, [21] and the minimized complex was then subjected to 10 ns of MD simulation by using Amber 11. [22] The ester of NHI-Glc-2 forms a H-bond with R169 (Figure 2 ), similarly to that found by MD simulation of ester-aglycone NHI-2.
[16b] The indole portion is in a pocket defined by N138, H193, G194, A238, and Y239, with its 6-phenyl substituent protruding toward the enzyme cavity entrance channel. The glucose moiety establishes strong interactions at the NADH-binding pocket, in particular, H-bonds with Asn138 and with the backbone of Val136 and Ser137 (Figure 2 B and Table S1 ). These additional interactions largely compensate for the loss of those involving the N-OH group of non-conjugated derivatives. Interestingly, both Val136 and Asn138 were previously found to be similarly involved in crucial interactions with the enzyme cofactor, NADH, in the X-ray structure of the complex of LDH-A with NADH and oxamate (PDB ID: 1I10). [23] Evaluation of these compounds against a panel of cancer cell lines representing the types of cancers in which LDH-A [12b, 26] and GLUT-1 [27] are commonly highly expressed demonstrated that NHI-Glc-1 was inactive (IC 50 > 200 mm in HeLa cells); however, NHI-Glc-2 had three-to fivefold and six-to ninefold enhanced potency over NHI-2 and NHI-1, respectively (Table 1 ). All compounds were significantly less potent against non-cancerous mouse embryonic fibroblasts (WT-MEF, Table 1 ).
To assess efficacy in inhibiting lactate production in cells, HeLa cells were treated with varying concentrations of NHIs and other reported LDH-A inhibitors, including FX-11, [19a] galloflavin, [21] and the AstraZeneca compound AZ 33 [22] (structures Figure S2 ). After 8 h of treatment, the lactate content in cell culture media was quantified by GC-MS. This GC-MS assay for lactate detection has several-fold increased sensitivity relative to the 13 C NMR-based assay previously employed, [16a] and allows precise detection of lactate at low micromolar concentrations (unlike the low millimolar detection limit of 13 C NMR). Consistent with the proliferation assay results, NHI-Glc-1 had only modest effects at 200 mm (Figure 3 A) , similar to its aglycone NHI-1 (500 mm for substantial efficacy). [16a] In contrast, treatment with NHI-Glc-2 led to significant, dose-dependent reduction in cellular lactate production (more potent than the aglycone NHI-2). The hexokinase inhibitor 2-deoxyglucose also had modest effect at very high concentrations (10 mm), whereas negligible effects were observed for inhibitors FX-11, galloflavin, and AZ 33 (each at 100 mm). Cytotoxic compounds that do not impact glucose metabolism, such as the topoisomerase II inhibitor etoposide, had no effect on lactate production. Furthermore, the reduction in lactate production observed with the NHIs preceded the onset of cell death ( Figure S3 ).
To test if the enhanced cancer cell toxicity and lactate production inhibition by NHI-2 and NHI-Glc-2 was attributable to enhanced cell uptake, the ability of these compounds to penetrate A549 cells was evaluated. To compare the relative intracellular concentrations, A549 cells were treated with equimolar amounts of compound or vehicle for 4 h, cell lysates were subjected to LC-MS analysis, and lysate concentrations were determined by using calibrations with known concentrations generated by the same LC-MS protocol ( Figure S4 ). In lysate from A549 cells, NHI-2 was present in approximately 4.5-fold higher concentration than NHI-1, and NHI-Glc-2 concentration was approximately 24-fold higher (Figure 3 B) . NHI-Glc-2 did not appear to be appreciably cleaved to either NHI-2 or NHI-Glc-1 inside the cell (representative UV traces in Figure S5 ).
To examine whether NHI-Glc-2 enters cells via GLUT transporters, a competition assay was performed between NHI-Glc-2 and GB2-Cy3, a fluorescent Cy3-linked glucose bioprobe recently developed by Park and coworkers. [28] A number of glucose bioprobes are known, [29] but GB2-Cy3 has been shown to exhibit enhanced fluorescence in live cells and enhanced ability to compete with glucose for uptake into cultured cells, compared to the known 2-deoxyglucose analogue 2-[N-(7-nitrobenx-2-oxa-1,3-diazol-4-yl)-amino]-2-deoxy-d-glucose (2-NBDG): 5 mm GB2-Cy3 is more potent than 50 mm 2-NBDG in inhibiting glucose uptake.
[30] For our purposes, cellular fluorescence was used as a readout for cellular uptake of GB2-Cy3. A549 cells, which highly express GLUT-1, [27b] were treated for 30 min with 2.5 mm GB2-Cy3 in the presence of either vehicle or 10 mm NHI-2, NHI-Glc-2, or glucose. Cells were then imaged by confocal laser scanning microscopy, and fluorescence was quantified and averaged over 40-60 cells. Treatment with NHI-Glc-2 and glucose caused a statistically significant decrease in fluorescence compared to vehicle, whereas treatment with NHI-2 did not (Figure 4) , thus suggesting that NHI-Glc-2 and glucose compete with GB2-Cy3 for cellular entry through GLUT transporters. To confirm that loss of cell viability was not skewing this result, 30 min toxicity assays were performed for both NHI-2 and NHI-Glc-2; the results show that no appreciable loss of viability is observed during a 30 min treatment with up to 200 mm compound (Figure S3 A) .
In summary, NHI-Glc-2 has been designed as the first compound aimed at dual targeting of the Warburg effect, that is, to exploit 1) enhancement in glucose uptake, and 2) the in- Figure 3 . A) Treatment of HeLa cells with various compounds shows that NHI-Glc-2 dose-dependently reduces lactate production more efficiently that NHI-2. It is also significantly more potent than NHI-1, NHI-Glc-1, and other reported LDH-A inhibitors, FX-11, galloflavin, and AZ 33. HeLa cells were treated for 8 h with compound (1 % in DMSO) or DMSO (vehicle) in DMEM. To quantify lactate production, cell culture media were analyzed by GC-MS. Lactate peaks were normalized with an internal standard in each sample (error bars denote SE of three or more independent experiments). B) Compound NHI-Glc-2 is more readily taken up by cancer cells than NHI-1 or NHI-2. A549 cells were treated with compound (100 mm) or vehicle (final, 0.2 % DMSO). Cells were collected after 4 h, washed twice in PBS, sonicated in methanol, and analyzed by LC-MS. UV trace integration areas (standardized by sample fresh weights) were converted to relative concentrations by using calibration of known concentrations ( Figure S4 ). Concentrations are presented relative to concentration of NHI-1 (error bars show SE of three or more independent experiments).
creased glycolysis that characterizes many aggressive tumors. NHI-Glc-2 has improved potency against cancer cells and shows increased cell permeability compared to its aglycone; the modest reduction in inhibition potency on isolated enzyme is highly compensated for by improved cellular uptake via GLUT transporters. This compound will be an outstanding tool to fully probe the tractability of LDH-A inhibition in advanced mammalian tumor models. In addition, these results support application of this dual targeting strategy to other anticancer agents targeting tumor metabolism. The Q-Tof Ultima mass spectrometer was purchased in part with a grant from the National Science Foundation, Division of Biological Infrastructure (DBI-0100085). Dr. Giorgio Placanica of the University of Pisa is gratefully acknowledged for technical assistance in the analysis of chemical products. GB2-Cy3 was a kind gift from Prof. Seung Bum Park at Seoul National University.
Keywords: cancer · drug design · glycoconjugation · targeted anticancer agents · Warburg effect Figure 4 . A549 cells were grown in RPMI 1640 media on covered glass-bottomed dishes (60 000 cells/dish). When cells reached 70 % confluence, they were treated with GB2-Cy3 (2.5 mm) either A) alone, or in the presence B) NHI-2 (10 mm), C) NHI-Glc-2 (10 mm), or D) glucose (10 mm) for 30 min at 37 8C. Cellular fluorescence was observed with a Zeiss LSM700 confocal microscope (photomultiplier gain 844, laser power 555 nm). E) Intracellular fluorescence of cells treated with NHI-Glc-2 or glucose is statistically significantly less than that for vehicle-treated cells, thus indicating that uptake of fluorescent GB2-Cy3 probe was inhibited by treatment with NHI-Glc-2 and glucose. The mean fluorescence intensity of each sample was calculated by averaging the fluorescence intensities of 40-60 cells from three independent experiments. Error bars show SE (n = 3); statistical analysis was performed using an unpaired, two-tailed Student's t test. * p < 0.05; ** p < 0.01.
